Details of Drug Interaction

Details of Drug-Drug Interaction

 Drug General Information (ID: DDIJB0PF5T)
  Drug Name Adalimumab Drug Info Daratumumab Drug Info
  Drug Type Monoclonal antibody Monoclonal antibody
  Therapeutic Class Antirheumatics Antineoplastics/Cd38 Monoclonal Antibodies

 Mechanism of Adalimumab-Daratumumab Interaction (Severity Level: Major)
     Additive immunosuppressive effects Click to Show/Hide Mechanism Graph
Could Not Find 2D Structure
      Drug Name Adalimumab Daratumumab
      Mechanism Immunosuppressive effects Immunosuppressive effects
      Key Mechanism Factor 1
Factor Name Immunosuppressive effects
Factor Description Immunosuppression is when your immune system is not functioning as it should. The immune system is made up of cells, tissues and organs that help the body fight off infections. If the immune system is suppressed, an infection that your body was able to control may become serious or even fatal.
      Mechanism Description
  • Additive immunosuppressive effects by the combination of Adalimumab and Daratumumab 

Recommended Action
      Management Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections. TNF blocker therapy should be discontinued if a serious infection or sepsis occurs. Close monitoring for signs and symptoms of HSTCL (e.g., splenomegaly, hepatomegaly, abdominal pain, persistent fever, night sweats, weight loss) is also recommended during use of TNF blockers, particularly in combination with other immunosuppressants such as azathioprine and mercaptopurine.

References
1 Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
2 Product Information. Enbrel (etanercept). Wyeth-Ayerst Laboratories, Philadelphia, PA.
3 Product Information. Humira (adalimumab). Abbott Pharmaceutical, Abbott Park, IL.
4 Product Information. Remicade (infliximab). Centocor Inc, Malvern, PA.
5 Product Information. Simponi (golimumab). Centocor Inc, Malvern, PA.
6 FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Drug labels for the Tumor Necrosis Factor-alpha (TNFa) blockers now include warnings about infection with Legionella and Listeria bacteria. ".